SCHEDULE 13G/A: BlackRock Discloses 6.6% Stake in Jade Biosciences
Beneficial Ownership Report
BlackRock, Inc. has reported a 6.6% beneficial ownership in JADE BIOSCIENCES INC, holding 2,150,203 shares of common stock as of September 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,150,203 shares of JADE BIOSCIENCES INC common stock.
- This ownership represents 6.6% of the total outstanding common stock of JADE BIOSCIENCES INC.
- BlackRock holds sole voting power over 2,094,378 shares and sole dispositive power over 2,150,203 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Asset Management Canada Limited, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, are identified as entities that may beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: The disclosure of a significant 6.6% stake by a major institutional investor like BlackRock is generally viewed positively, indicating confidence in the company's long-term prospects, even if it's a passive investment.
Positives
- Significant institutional investment by BlackRock, Inc. indicates potential confidence in JADE BIOSCIENCES INC's long-term prospects.
- BlackRock's acquisition of shares is stated to be in the ordinary course of business, not for control, suggesting a passive investment strategy.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding JADE BIOSCIENCES INC's operational or financial performance.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Industry Context
Institutional filings like Schedule 13G provide transparency into significant ownership stakes by large asset managers, offering insights into investor sentiment and capital allocation trends within the biotechnology or life sciences sector, where JADE BIOSCIENCES INC likely operates.
Stakeholder Impact
- Shareholders: Increased institutional ownership may enhance market confidence and liquidity for JADE BIOSCIENCES INC shares.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Execution date of the current Power of Attorney by BlackRock, Inc. |
| 2025-09-30 | Date of event requiring the filing of this statement, when BlackRock's beneficial ownership reached the reporting threshold. |
| 2025-10-17 | Filing date of the Schedule 13G by BlackRock, Inc. |
Keywords
JADE BIOSCIENCES INC, BlackRock, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Beneficial Ownership, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.